Safety of anacetrapib in patients with or at high risk for coronary heart disease
| Autor: | Christopher P, Cannon, Sukrut, Shah, Hayes M, Dansky, Michael, Davidson, Eliot A, Brinton, Antonio M, Gotto, Michael, Stepanavage, Sherry Xueyu, Liu, Patrice, Gibbons, Tanya B, Ashraf, Jennifer, Zafarino, Yale, Mitchel, Philip, Barter, T O, Wahl |
|---|---|
| Přispěvatelé: | Twickler, Marcel, DEFINE Investigators |
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Statin medicine.drug_class Dalcetrapib Coronary Disease chemistry.chemical_compound Young Adult Double-Blind Method Anacetrapib Risk Factors Internal medicine Cholesterylester transfer protein medicine Humans CETP inhibitor Oxazolidinones Aged biology business.industry Cholesterol Anticholesteremic Agents Cholesterol HDL Torcetrapib Bayes Theorem General Medicine Cholesterol LDL Middle Aged Combined Modality Therapy Surgery Cholesterol Ester Transfer Proteins chemistry Cardiology biology.protein lipids (amino acids peptides and proteins) Female Human medicine business Evacetrapib |
| Zdroj: | The New England journal of medicine |
| ISSN: | 1533-4406 0028-4793 |
| Popis: | Background Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. Methods We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease or at high risk for coronary heart disease. Eligible patients who were taking a statin and who had an LDL cholesterol level that was consistent with that recommended in guidelines were assigned to receive 100 mg of anacetrapib or placebo daily for 18 months. The primary end points were the percent change from baseline in LDL cholesterol at 24 weeks (HDL cholesterol level was a secondary end point) and the safety and side-effect profile of anacetrapib through 76 weeks. Cardiovascular events and deaths were prospectively adjudicated. Results A total of 1623 patients underwent randomization. By 24 weeks, the LDL cholesterol level had been reduced from 81 mg per deciliter (2.1 mmol per liter) to 45 mg per deciliter (1.2 mmol per liter) in the anacetrapib group, as compared with a reduction from 82 mg per deciliter (2.1 mmol per liter) to 77 mg per deciliter (2.0 mmol per liter) in the placebo group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|